ASK1/JNK inhibitors very effectively suppressed OSCS induced by OTUD1 overexpression (Fig. 6), and ibrutinib, an FDA-approved MKK7 inhibitor, preferentially reduced the tumorigenicity of OTUD1high ovarian cancer cells (Fig. 7). This evidence concerns the gene MAP2K7 and ovarian carcinoma.